Navigation Links
Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings

WASHINGTON, May 30, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the Phase III studies of tasimelteon in Non-24-Hour Disorder (Non-24) will be presented at SLEEP 2013, the 27th Annual Meeting of the Associated Professional Sleep Societies, LLC being held from June 1, 2013 through June 5, 2013 in Baltimore and the Endocrine Society's 95th Annual Meeting (ENDO) being held June 15, 2013 through June 18, 2013 in San Francisco.  Non-24 is a serious and rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (synchronize) their master body clock to the 24-hour day. 

Tasimelteon data at SLEEP 2013 will be presented as a late breaking abstract and the data at ENDO 2013 will be presented in a poster and oral presentation.  The data presentation schedule is as follows:

-- SLEEP 2013 Baltimore
Late Breaking Abstract #005 June 5, 2013 at 12:15 PM-1:30 PM

-- ENDO 2013 San Francisco
SUN-134 June 16, 2013 at 1:45 PM – 3:45 PM
SUN-137 June 16, 2013 at 1:45 PM – 3:45 PM

About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle. Non-24 affects the majority of totally blind individuals, or between 65,000 and 95,000 people in the U.S.  Non-24 occurs almost entirely in individuals who lack the light sensitivity necessary to entrain the master body clock in the brain with the 24-hour day-night cycle.  Most people have a master body clock that naturally runs longer than 24-hours and light is the primary environmental cue that resets it to 24-hours each day.  Individuals with Non-24 have a master body clock that continually delays, resulting in prolonged periods of misalignment  between their circadian rhythms and the 24-hour day-night cycle, including the timing of melatonin and cortisol secretion and the sleep-wake cycle.  As a result of this misalignment, Non-24 is associated with significant impairments in social and occupational functioning, and marked subjective distress.  For more information on Non-24, please visit

About Tasimelteon
Tasimelteon is a circadian regulator in development for the treatment of Non-24.  Tasimelteon is a dual melatonin receptor agonist (DMRA) with selective agonist activity at the MT1 and MT2 receptors.  Tasimelteon's ability to reset the master body clock in the suprachiasmatic nucleus (SCN) results in the entrainment of the body's melatonin and cortisol rhythms with the 24-hour day-night cycle.  The patent claiming tasimelteon as a new chemical entity extends through December 2022, assuming a 5-year extension to be granted under the Hatch-Waxman Act.  Tasimelteon has been granted orphan drug designation for the treatment of Non-24 from both the U.S. and the European Union. 

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit  

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

Media Contact:
Laney Landsman
Assistant Vice President
(212) 508-9643  


SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
2. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
3. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
4. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
5. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
7. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
8. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
9. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
10. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
11. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
Post Your Comments:
(Date:12/1/2015)... December 1, 2015 Biovicas ... Study Group (IBCSG, Bern ) ... i en klinisk studie av palbociclib, ett nytt ... --> Studien, med namn PYTHIA, kommer följa ... läkemedel i kombination med palbociclib, som tillhör klassen ...
(Date:11/30/2015)... Dec. 1, 2015 Researchers have developed software ... part thickness and checks for motion, positioning and beam ... study presented today at the annual meeting of the ... (RSNA). Steven Don , M.D., associate professor ... School of Medicine in St. Louis, Mo. ...
(Date:11/30/2015)... TOKYO , 1. Dezember 2015 /PRNewswire/ ... größte Messe und Konferenz für Entwicklung ... 20. bis 22. April 2016 in ... Foto:- ... Logo: Logo: ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., ... Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the ... Center solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Trevor and Taylor Crabb have unveiled an exciting ... chance to represent the United States. This hybrid crowdfunding campaign is designed ... their journey in addition to offering corporate sponsors with some great marketing deliverables with ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of Professional ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... for professional women, boasting more than 850,000 members and over 200 operating Local Chapters. ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
Breaking Medicine News(10 mins):